Tromsø, Norway, March 27, 2024 - ArcticZymes Technologies ASA (OSE: AZT)
Research Paper on ArcticZymes R2D Ligase[TM] is published in the Biotechnology
Journal

ArcticZymes Technologies ASA is pleased to announce the release of a research
paper in the international peer-reviewed publication, Biotechnology Journal,
showcasing the features and potential of the patent pending ArcticZymes R2D
Ligase[TM]. This novel enzyme, introduced in 2021, has functionalities enabling
innovative advancements in RNA analysis, diagnostics and synthesis.

Authored by Sigurd Gundesø et al., the recent publication entitled "R2D Ligase:
Unveiling a Novel DNA Ligase with Surprising DNA-to-RNA Ligation Activity"
describes the uniqueness of the ArcticZymes R2D Ligase[TM ]and its specificity
and ability to ligate and bridge DNA-to-RNA.

Through dissemination of our research findings in peer-reviewed journals,
ArcticZymes aims to elevate awareness of our cutting-edge products and stimulate
the emergence of disruptive technologies. We are committed to driving forward
progress in the field, catalyzing innovation and paving the way for impactful
scientific breakthroughs.

Michael Akoh, CEO comments: "We are happy to see the publication of our research
paper on AZ R2D Ligase[TM] in the Biotechnology Journal. This marks a milestone
for ArcticZymes and underscores the innovative potential of our ArcticZymes R2D
Ligase[TM]. The insights shared in this publication highlight our commitment to
advancing biotechnology and driving meaningful progress in the field of
molecular biology. We are excited about the possibilities this enzyme presents
and look forward to further contributing to discoveries in RNA diagnostics and
synthesis."

Access the published article via this link:
http://dx.doi.org/10.1002/biot.202300711